Regarding monitoring for agranulocytosis in clozapine-treated patients, which statement is most accurate?

• A. Monitoring reduces incidence to around 0.38% (from about 1%)
• B. Monitoring eliminates risk
• C. Monitoring is only required in the first week
• D. Monitoring is optional

Answer: (A)

Regular blood monitoring is essential with clozapine because agranulocytosis, a serious drop in neutrophils, can develop rapidly, especially early in treatment. Checking the absolute neutrophil count (and stopping the drug if it falls too low) allows clinicians to catch neutropenia before it progresses to agranulocytosis, significantly reducing risk. Data from monitoring programs show the incidence drops from about 1% without strict monitoring to roughly 0.38% with it, illustrating how early detection and intervention lower the chance of a dangerous event. However, the risk is not zero, and stopping the medication promptly when counts fall is crucial. The monitoring is not limited to the first week and is not optional in standard care.